Childhood CancerNCT02959086
Shanghai Epidemiology Study for Adolescents and Children With Cancer
An observational study of Childhood Cancer, run by Children's Cancer Group, China at 2 sites in China.
Trial summary
The purpose of this study is to describe the morbidity, mortality, disability and survival rate in Shanghai adolescents and children with cancer diagnosed since January 2002. Read more about this study
- Who is it for?
- Ages 0 to 19 years
- Conditions the study is for
- Childhood Cancer
- How many people
- 2,000 participants
- Where
- 2 sitesChina
- Study dates
- Jan 2002to Jan 2030
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 19 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Since January 2002 in Shanghai, 0-19 year-old children and adolescents diagnosed with cancer.
Who may be able to join
- 0-19 year-old children and adolescents.
- Diagnosed cancer in Shanghai since January 2002.
Who cannot join
- Patients who were lost of follow-up.
- Patient's death wasn't caused by cancer or complications but by other accidents such as car accident, fell from a great height and so on.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China2 sites, 1 recruiting
- Active, not recruiting
Shanghai Children's Medical Center
Shanghai, Shanghai Municipality, 200127
- Recruiting
Shanghai Municipal Center of Disease Prevention & Control
Shanghai, Shanghai Municipality, 200336
Ying Zheng, MS,MD, 0086-21-62758710
Liang Shi, MD,MPH, 0086-21-62758710, shiliang@scdc.sh.cn
About this study
The purpose of this study is to describe the morbidity, mortality, disability and survival rate in Shanghai adolescents and children with cancer diagnosed since January 2002.
Read the detailed description
The investigators collected information of all the adolescents and children diagnosed cancer in Shanghai since January 2002, including their name, gender, the date of birth, the diagnosis date, disease diagnosis, residence address and the last follow-up time status (survival/death). The type of cancer included all malignant tumors such as Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, central nervous system tumors, Neuroblastoma, Wilms tumor and so on. Then the investigators would analyze the morbidity, mortality, disability and survival rate.
- Conditions
- Childhood Cancer
- Keywords
- Epidemiology, Shanghai, Cancer, Adolescents, Children
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Patients were diagnosed since January 2002. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival for the whole cohort
Measured: 5 years
Secondary outcomes (1)
Mortality for the whole cohort
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2016 (estimated)
- Study startJan 2002
- Primary completionApr 2017
- Study completionJan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Childhood CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Children's Cancer Group, China
- Sponsor type
- Research network
- Collaborators
- Shanghai Children's Medical Center, Shanghai Municipal Center for Disease Control and Prevention
- Responsible party
- Sponsor
- Investigators
- Yi-Jin Gao, MD, Principal investigator, Shanghai Children's Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02959086
- Sponsor's protocol ID
- CCGChina
- Status last verified
- Oct 2026
- First submitted
- 7 Nov 2016
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Shanghai Epidemiology Study for Adolescents and Children With Cancer
- ClinicalTrials.gov ID
- NCT02959086
- Acronym / sponsor ID
- CCGChina
- Conditions
- Childhood Cancer
- Keywords
- Epidemiology, Shanghai, Cancer, Adolescents, Children
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Children's Cancer Group, ChinaResearch network
- Collaborators
- Shanghai Children's Medical Center, Shanghai Municipal Center for Disease Control and Prevention
- Study start
- Jan 2002 (actual)
- Primary completion
- Apr 2017 (actual)
- Study completion
- Jan 2030 (estimated)
- First posted
- 8 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to describe the morbidity, mortality, disability and survival rate in Shanghai adolescents and children with cancer diagnosed since January 2002.
Detailed description
The investigators collected information of all the adolescents and children diagnosed cancer in Shanghai since January 2002, including their name, gender, the date of birth, the diagnosis date, disease diagnosis, residence address and the last follow-up time status (survival/death). The type of cancer included all malignant tumors such as Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, central nervous system tumors, Neuroblastoma, Wilms tumor and so on. Then the investigators would analyze the morbidity, mortality, disability and survival rate.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | – | –Patients were diagnosed since January 2002. |
Who may qualify
- Ages
- 0 to 19 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Since January 2002 in Shanghai, 0-19 year-old children and adolescents diagnosed with cancer.
Key inclusion criteria (2 listed)
- 0-19 year-old children and adolescents.
- Diagnosed cancer in Shanghai since January 2002.
Key exclusion criteria (2 listed)
- Patients who were lost of follow-up.
- Patient's death wasn't caused by cancer or complications but by other accidents such as car accident, fell from a great height and so on.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall survival for the whole cohort
Time frame: 5 years
1 secondary outcome
Mortality for the whole cohort
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Childhood Cancer
Not yet recruitingPhase 1/2
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
RecruitingPhase 3
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
B-Cell Acute Lymphoblastic Leukaemia
RecruitingObservational study
Pharmacokinetics of Dexamethasone in Childhood ALL and Reduction in Bone Mineral Density
Acute Lymphoblastic Leukemia
RecruitingObservational study
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Acute Ovarian Failure, Infertility
RecruitingObservational study
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Very Rare Tumors, Very Rare Cancers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yi-Jin Gao, MD principal investigator
Shanghai Children's Medical Center
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Childhood Cancer, run by Children's Cancer Group, China at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yi-Jin Gao, MD (0086-21-38626161, gaoyijin@scmc.com.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival for the whole cohort (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.